INTRODUCTION
The symptoms of HD include uncontrollable choreic movements and mood disturbances that progress until death, which typically occurs ten to twenty years after disease onset (1) (2) . There is an inverse correlation between the age of symptom onset and the length of a polyglutamine tract encoded by a CAG repeat within exon 1 of the IT15 gene (3-5).
With disease progression, there is increasing loss of particular neuronal subtypes in the striatum and cerebral cortex of HD patients and, to a lesser degree, in other brain regions as well (6). It is unclear why, even within the severely affected striatum, subsets of neurons are differentially sensitive to mutant Htt. Transcriptional profiling studies of striatal and cortical postmortem tissue from HD patients and mouse models of HD have, however, identified candidate susceptibility factors as well as potentially protective, compensatory changes in gene expression (7-10).
One of the most significant transcriptional changes indicated by microarray studies of HD patients and animal models is the down-regulation of CalDAG-GEFI (a.k.a.
RasGRP2) (7-9, 11). CalDAG-GEFI encodes a notably striatum-enriched cytoplasmic signaling molecule that has binding sites for calcium and diacylglycerol (DAG) and nucleotide exchange factor domains that target the small G proteins, Rap1 and Rap2 (12-14). We have shown that signaling from CalDAG-GEFI to Rap-family GTPases in platelets and neutrophils is critical for integrin-dependent cell adhesion and vesicle release in vivo (13, (15) (16) . In the brain, we have shown that CalDAG-GEFI is predominantly expressed in medium spiny projection neurons of the striatum (12, 17) and in a subset of cortical neurons, cell types that are selectively destroyed in HD.
CalDAG-GEFI is not expressed at high levels by striatal interneurons, which are relatively spared in HD (18) (19) . Further, CalDAG-GEFI is differentially enriched in the matrix compartment of the striatum, relative to its levels in the striosomal compartment (12). This differential distribution is significant in light of evidence that, within the HD striatum, predominant neurodegeneration can occur in either one of these two striatal compartments (20) (21) (22) (23) and is correlated with distinct symptom profiles (22) .
Given this evidence, we examined CalDAG-GEFI protein expression in HD and HD mouse models and directly tested in an in vitro HD striatal assay whether CalDAG-GEFI expression could influence striatal pathology. We found that CalDAG-GEFI was downregulated in postmortem striatal samples from intermediate-and late-stage HD patients, as well as in the striatum of both the R6/1 and R6/2 mouse models of HD. In the R6/2 mouse striatum, we tracked the timing of CalDAG-GEFI down-regulation and found it to correspond to the timing of disease progression. Unexpectedly, we found that the degree of down-regulation was strongly correlated with the size of the polyglutamineexpanded Htt aggregates in striatal neurons. We therefore examined the possibility that reduced CalDAG-GEFI might mitigate cellular vulnerability to mutant Htt. We found that knock-down of CalDAG-GEFI expression protected striatal neurons from the severe pathology induced by polyglutamine-expanded Htt exon 1 in an organotypic striatal slice culture. These findings raise the clinically interesting possibility that reduced expression of CalDAG-GEFI in HD occurs as a neuroprotective mechanism to limit Htt-induced neuropathology.
RESULTS

CalDAG-GEFI is down-regulated in Huntington's Disease
To test whether the expression of CalDAG-GEFI protein is disrupted in HD, we obtained postmortem tissue from the striatum of three patients with Huntington's disease, one with intermediate-stage HD (Grade II-III) and two with late-stage HD (Grade IV) (6), and from sex-matched control brains that did not show striatal pathology. Western blot analysis showed that CalDAG-GEFI immunoreactivity was diminished in the striatal samples from all three HD brains, relative to those from the control brains (Fig. 1A ).
Based on comparison with a standard curve generated from 2X to 0.25X serial dilutions of the pooled control samples, this corresponded to 34 ± 12% (mean ± SEM) less CalDAG-GEFI protein in the HD striatum than in controls (Fig. 1A) . These results confirm and extend the finding in microarray studies of severe down-regulation of CalDAG-GEFI mRNA in the striatum of HD patients (8-9).
To establish an experimental model for testing the effects of CalDAG-GEFI in HD, we next tested for the loss of CalDAG-GEFI in the most widely characterized mouse model of HD, the R6/2 line (24). R6/2 mice carry a transgene encoding the first exon of human IT15 with a CAG expansion of over 140 repeats. The onset of motor impairments occurs in these mice before 8 weeks of age, and their symptoms develop to include choreic and stereotypic movements, tremor and seizures that progress until death, at about 13 weeks of age (24). Severe shrinkage of brain neuropil occurs in the R6/2 mice, but cell death is minimal by comparison with that occurring in HD patients (24-25).
In Western blots of brain tissue lysates from 12 week-old R6/2 mice, we found that CalDAG-GEFI immunoreactivity was reduced by 49% in the striatum (P < 0.02) and 40% in neocortex (P < 0.03), relative to that measured in age-matched controls (Fig. 1B and C). By contrast, there was not a significant difference in the expression of CalDAG-GEFI in hippocampal lysates from the two genotypes (P > 0.6; Fig. 1D ), suggesting that the down-regulation of CalDAG-GEFI is limited to specific brain regions. We tracked the development of this deficit by harvesting brain tissue from R6/2 mice and littermate controls at 4, 8 and 12 weeks of age and examining the distribution of CalDAG-GEFI protein by immunohistochemistry (Fig. 1E) . The immunoreactivity appeared slightly diminished in striatal brain sections from 4 week-old R6/2 mice (Fig. 1E) , a time-point at which transcriptional changes are modest (10), but phenotypic abnormalities become apparent (10, 26-28). We observed progressive loss of CalDAG-GEFI immunostaining in 8 and 12 week-old R6/2 mice (Fig. 1E ), ages at which increasingly severe motor complications occur (24). We also examined CalDAG-GEFI expression in symptomatic, 9 month old R6/1 mice, which carry the same transgene as R6/2 mice, but which exhibit a slower disease progression as a result of reduced transgene expression (24). We observed severely diminished CalDAG-GEFI immunoreactivity in these late-stage mice as well (Fig. 1F) . CalDAG-GEFI immunostaining was clearly matrix-predominant at each age in both the R6/1 and R6/2 mutants and the control mice ( Fig. 1G and H ). These findings demonstrate that, with disease progression and increasing severity of disease symptoms, CalDAG-GEFI expression is progressively lost in the striatum of R6/1 and R6/2 mice, as in the human HD striatum, and that the loss is selective for the matrix compartment of the striatum.
To examine further the tissue-specificity of CalDAG-GEFI down-regulation, we measured CalDAG-GEFI expression and function in platelets from R6/2 mice. CalDAG-GEFI is strongly expressed in platelets from normal mice and is critical for integrindependent platelet adhesion and aggregation (13, 29) . Western blots of platelet lysates from 12 week-old R6/2 mice and age-matched controls showed no significant differences in CalDAG-GEFI expression (Supplementary Material, Fig. S1A ).
Furthermore, we found that platelets from 12 week-old R6/2 mice undergo normal CalDAG-GEFI-mediated aggregation (Supplementary Material, Fig. S1B ). Thus, the down-regulation of CalDAG-GEFI that occurs in striatum and cortex of R6/2 mice is not a generalized effect in all cells expressing CalDAG-GEFI.
CalDAG-GEFI expression is inversely correlated with Htt aggregate size in R6/2 model mice
In R6/2 mice, we observed that a subset of striatal neurons maintained normal levels of CalDAG-GEFI immunoreactivity in their cell bodies, despite the overall down-regulation of striatal CalDAG-GEFI expression ( Fig. 2A, right panel) . These neurons appeared to be of the medium-sized neuronal phenotype that characterizes striatal projection neurons, which are normally enriched in CalDAG-GEFI (12, 17). Further, we found that these neurons co-expressed EGFP reporter genes that mark the expression of the striatum-enriched D1 and D2 dopamine receptors ( Fig. 2B and C) (30) . Thus, the scattered neurons with high levels of CalDAG-GEFI expression in the striatum of R6/2 mice appeared to be dopaminoreceptive neurons that had not undergone downregulation of CalDAG-GEFI. Spurred by this observation, we examined the same brains to determine which striatal neurons exhibited Htt protein aggregates, a neuropathologic hallmark of HD (31-32). Aggregates of mutant Htt are found in the nucleus and cytoplasm of neurons throughout the neocortex and, to a lesser degree, the striatum of patients with HD and R6/2 model mice (33-35). In accord with these findings, Httpositive neuronal intranuclear inclusions were abundant in the striatum and neocortex of the 12 week-old R6/2 mice (Fig. 2D, right panel) .
We found a striking correspondence between the striatal neurons that maintained CalDAG-GEFI expression and the striatal neurons that lacked Htt-positive nuclear inclusions. Figure 2D shows the results of experiments in which we detected immunoreactivity for CalDAG-GEFI with antibodies conjugated to a red fluorophore and detected Htt with antibodies conjugated to a green fluorophore. CalDAG-GEFI did not colocalize with the intranuclear Htt inclusions (Fig. 2E) , indicating that the loss of CalDAG-GEFI staining in the cytoplasm was not the result of sequestration in Htt inclusions. We applied deconvolution microscopy to obtain volumetric measurements of Htt-positive nuclear inclusions in striatal neurons that had high, intermediate or low levels of CalDAG-GEFI immunostaining. Striatal neurons with low levels of CalDAG-GEFI had nuclear inclusions that were roughly three-fold larger than the nuclear inclusions in striatal neurons with high levels of CalDAG-GEFI immunostaining ( Fig. 2F and G). This inverse correlation between Htt-positive inclusion volume and CalDAG-GEFI expression was highly significant (P < 0.0001).
Knock-down of CalDAG-GEFI expression is neuroprotective in a brain slice model of HD
To test whether changes in CalDAG-GEFI expression levels could influence the cellular pathology associated with HD, we performed CalDAG-GEFI over-expression and knock-down experiments in a rat organotypic cortico-striatal slice model of HD (36) (37) (38) .
A biolistic device was used to transfect these explants with exon 1 of human Htt bearing a polyglutamine expansion of 73 polyglutamines. In this system, the transfection of polyglutamine-expanded Htt exon 1 has been shown to induce progressive dendritic and cell body degeneration of medium spiny striatal neurons that can be visualized by co-transfection with yellow fluorescent protein (YFP; Fig. 3A-D) (36) (37) (38) .
As in these previous studies, we observed that the number of healthy striatal neurons was reduced by ~2-fold in brain slices that were transfected with the mutant Htt construct, relative to the numbers found in the striatum of control slices transfected with YFP marker alone ( Fig. 3E , P < 0.01). However, when we co-transfected cortico-striatal brain slices with the polyglutamine-expanded Htt exon 1 and with an siRNA that targets CalDAG-GEFI (15), the numbers of healthy striatal neurons were restored to control levels, relative to the numbers of healthy neurons in slices that were co-transfected with a control siRNA ( Fig. 3E , P < 0.01). To ensure that the siRNA effectively knocked down rat CalDAG-GEFI, we transfected the rat striatal cell line ST14A with increasing concentrations of siRNA. We observed a dose-dependent reduction in CalDAG-GEFI protein expression, relative to cells transfected with a non-targeting control siRNA (Fig.   3F ). We also confirmed that the siRNA was effective in the explant system. We cotransfected slices with YFP, siRNA and a CalDAG-GEFI-tdTomato fusion construct and then evaluated the tdTomato fluorescence intensity of medium spiny striatal cells that were co-tranfected with CalDAG-GEFI siRNA vs. control siRNA (Supplementary Material, Fig. S2 ). In the slices that were co-transfected with CalDAG-GEFI siRNA, we found that there were significantly more cells classified as dim (P < 10 -5 ), and significantly fewer cells classified as bright (P < 10 -5 ), for expression of the CalDAG-GEFI-tdTomato protein, relative to slices transfected with control siRNA. Thus, the siRNA targeting CalDAG-GEFI effectively knocked-down expression of the CalDAG-GEFI-tdTomato fusion construct in the explant system.
As a control for the effects of CalDAG-GEFI knock-down alone, we repeated these experiments, transfecting the CalDAG-GEFI siRNA without co-transfection of the mutant Htt construct. There was no change in the numbers of healthy neurons relative to treatment with the control siRNA, demonstrating that the rescue effect of the CalDAG-GEFI siRNA was specific to the presence of mutant Htt exon 1 (Fig. 3G ). When we transfected YFP siRNA alone, the number of visible YFP-positive neurons visible was minimal, reflecting nearly complete knock-down of YFP protein expression and indicating that the siRNA transfection system itself was effective (Fig. 3G) . Finally, we co-transfected slices with a CalDAG-GEFI over-expression construct together with the Htt construct and YFP. Whereas knock-down of CalDAG-GEFI rescued mutant Htt exon 1-induced pathology in the slice system, over-expression of CalDAG-GEFI tended to exacerbate the toxic effects of mutant Htt on the striatal neurons ( Fig. 3H , P = 0.05).
DISCUSSION
Our findings suggest that the striatum-enriched signaling molecule, CalDAG-GEFI, may be functionally linked to neuronal degeneration in HD. CalDAG-GEFI protein levels were markedly decreased in the striatum of intermediate-and late-stage HD human brains examined and in the striatum of symptomatic R6/1 and R6/2 HD model mice. The downregulation appeared to be tissue-specific, given that CalDAG-GEFI expression was normal in the hippocampus and in platelets from R6/2 mice with end-stage disease.
This tissue-selectivity of CalDAG-GEFI down-regulation stands in contrast to the regulation of numerous other genes that show parallel dysregulation in both brain and non-nervous system tissue in R6/2 mice, as tested in brain and muscle microarray assays (10).
Scattered cells within the striatum of R6/2 mice maintained high levels of CalDAG-GEFI expression, and these cells had markedly smaller Htt-positive nuclear inclusions than did those with low CalDAG-GEFI expression. The CalDAG-GEFI-positive cells had the morphological appearance of medium-sized neurons and were dopaminoreceptive, judging from co-expression of EGFP BAC transgene reporters for either the Drd1a or the Drd2 dopamine receptors. These CalDAG-GEFI-enriched striatal neurons were presumed to be of the projection neuron phenotype, as CalDAG-GEFI mRNA is predominantly expressed in these neurons in wild-type animals (17) and CalDAG-GEFI protein is transported from the striatum to terminal sites in the pallidum and substantia nigra (12). Fig. S3 ). Thus, our data indicate that the beneficial effects of CalDAG-GEFI knock-down in the explant assay are not related to aggregate formation.
If this finding extends to striatal neurons in R6/2 mice, then aggregate formation might precede, and promote, CalDAG-GEFI down-regulation in this model. Together with our findings that CalDAG-GEFI is strongly down-regulated in the HD striatum, and that CalDAG-GEFI is lost gradually over time in the R6/2 striatum, our results suggest that in HD, striatal neurons increasingly down-regulate CalDAG-GEFI as cellular pathology progresses.
Our in vitro findings demonstrate that knock-down of CalDAG-GEFI expression, which mimics its down-regulation in HD and HD models, rescues striatal neurons from the neuropathology induced by polyglutamine-expanded Htt exon 1 (36) (37) (38) .
Conversely, over-expression of CalDAG-GEFI in the brain slice model exacerbated the neuronal pathology associated with expression of polyglutamine-expanded Htt in this assay. Whereas knock-down of CalDAG-GEFI provided complete rescue from the pathology that was measured in this assay system, overexpression of CalDAG-GEFI had only a modest effect. This contrast likely reflects the fact that basal levels of CalDAG-GEFI are already so high in striatal neurons that overexpression has relatively little effect on CalDAG-GEFI signaling pathways. Nevertheless, this set of results concordantly support the hypothesis that down-regulation of CalDAG-GEFI is neuroprotective against neurodegenerative processes induced by polyglutamineexpanded Htt exon 1.
The mechanisms that might underlie this effect are as yet unclear, but they could involve elimination of toxic conformations of Htt or down-regulation of calcium-induced cytotoxic signaling. The calcium binding motifs in CalDAG-GEFI suggest that the protein might be highly sensitive to excitotoxic signaling, suggested to occur in HD (42-43).
Experimentally-induced strong excitation of the neocortex elevates intracellular calcium and activates the extracellular-regulated kinases, ERK1/2, in striatal neurons (44-46). In heterologous cell culture systems, CalDAG-GEFI regulates ERK (12, 47). These findings raise the possibility that compensatory down-regulation of CalDAG-GEFI might influence ERK signaling in the HD models. However, the role of ERK1/2 activation in the pathogenesis of HD remains unclear. Activated ERK1/2 levels are elevated in the striatum of R6/2 mice, despite an apparent reduction in downstream ERK1/2 signaling (48). In cell culture, it has been shown that potentiation of the ERK1/2 signaling cascade diminishes cell-death caused by expanded Htt expression (44, 49). ERK1/2 signaling is also implicated in another hyperkinetic movement condition, L-DOPA-induced dyskinesia. ERK1/2 activity is elevated in models of L-DOPA-induced dyskinesia and blockade of this activity alleviates the abnormal movements. We previously have found, in a rat model of L-DOPA-induced dyskinesia, that the matrix-enriched CalDAG-GEFI is down-regulated, whereas the striosome-enriched paralog, CalDAG-GEFII, is upregulated (50) . We suggested that the opposing dysregulation of these two ERK1/2 regulators could contribute to the imbalance in striosome:matrix activity observed in models of L-DOPA-induced dyskinesia. Similarly, the down-regulation of CalDAG-GEFI in HD would be expected to have compartment-specific effects. However, to our knowledge, the dysregulation of ERK1/2 activity in relation to these compartments has not been examined in HD models. What is known is that either the striosome or the matrix compartment can be differentially affected in HD brains examined post-mortem, suggesting that compartmentalized gene expression is likely to be important in the etiology or expression of the disorder. CalDAG-GEFI is one of the most heavily down-regulated transcripts identified in microarray screens for transcriptome changes in HD and models of HD (7-9, 11). Our findings raise the possibility that this down-regulation could represent an endogenous, homeostatic mechanism countering neuronal dysfunction in the striatum in HD. If so, early regulation of CalDAG-GEFI expression could represent a novel therapeutic strategy for early intervention.
MATERIALS AND METHODS
Animal husbandry
Mice and rats were maintained under a standard light/dark cycle with free access to food and water. Procedures for the mouse studies were in strict accordance with the MIT Committee on Animal Care, accredited by AAALAC (USA), and with Home Office (UK) regulations. All procedures used for the rats were in strict accordance with Duke Institutional Animal Care and Use Committee guidelines.
Mouse brain immunolabeling
Brains were obtained from R6/1 and R6/2 female mice and age-matched controls 
Human tissue isolation
Frozen brain tissue was provided by the Neuropathology Core of the Massachusetts
Alzheimer Disease Research Center and was prepared as described by Vonsattel and coworkers (54) . The control samples were from 45, 82 and 92 year old males with no remarkable brain pathology, the HD case samples were from 48, 59 and 72 year old males who were judged to have moderate to severe degeneration of the striatum and scattered ubiquitin-positive intranuclear inclusions.
Immunoblotting
To prepare striatal tissue from mice, brains were removed from deeply anesthetized R6/2 male mice and age-matched sibling controls and striatal tissue was immediately dissected and frozen. Platelets were isolated by collecting blood into serum-separation tubes, spinning serum for 10 min at 3,000 X g and freezing platelet pellets on dry ice.
Samples from the human caudate nucleus and putamen were dissected from frozen sections. Tissue was homogenized in ice-cold modified RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1% NaDeoxycholate) with Complete protease inhibitor cocktail (Roche) and was centrifuged at 16,000 X g for 10 min to remove insoluble material. Supernatants were analyzed by bicinchoninic acid assays (Thermo Fisher Scientific) to determine total protein concentration. Protein (40 g lysate per lane) was resolved by SDS-PAGE and transferred to PVDF membrane (Millipore) by electroblotting. Blots were incubated with anti-CalDAG-GEFI rabbit polyclonal antiserum #3752 (13) and anti-rabbit antibody coupled to horseradish peroxidase prior to immunodetection with Western Lightening (PerkinElmer Inc.) according to the manufacturer's instructions. Blots were subsequently incubated with anti-β-tubulin (Cell Signaling Technology) or anti-Tuj1 (Abcam Inc.) antibodies to control for protein loading. Blots were scanned (UMAX), and the pixel density and size of the immunoreactive bands was calculated with ImageJ (NIH). To normalize for background signal and protein loading, the mean pixel density of an equivalently-sized area below the immunoreactive band was subtracted from each band and the result was divided by the mean pixel density of the normalized Tuj1 band. Normalized intensity results were averaged within genotypes for comparison.
Deconvolution microscopy
Sections through the striatum were processed as described above for immunohistochemistry except that sections were double-labeled by simultaneous incubation with rabbit anti-CalDAG-GEFI and mouse monoclonal EM48 anti-Htt antibodies (MAB5374; Chemicon International) followed by fluorescent secondary antibodies (anti-mouse coupled to ALEXA 488 and anti-rabbit coupled to ALEXA 564;
Invitrogen Corp.). Sections were mounted and coverslipped with Vectashield media (Vector Laboratories).
A 100X objective on a Zeiss Axioplan 2 microscope fitted with a Hamamatsu ORCA-ER digital camera was used to obtain images from the medial striatum in two sections each from the brains of three R6/2 female mice (12 week-old). Striatal neurons were rated as having high, medium or low levels of anti-CalDAG-GEFI immunofluorescence by observation through the red channel alone to prevent biased cell-selection based on inclusion size (visible only through the green channel). Subsequently, a Z-stack of images through each neuron (Z step = 0.5 m) was acquired on the green channel, using Openlab Improvision software. Automatic exposure normalization was followed to control for variable staining intensity among the sections. Z-series data were deconvolved using Volocity Improvision software, and volume measurements of the MAB5374-immunoreactive inclusions were calculated by Volocity. Brain slices were co-transfected with a YFP expression construct in all cases so that medium spiny neurons could be imaged and identified by their location within the striatum and by their characteristic dendritic arborization. Medium spiny neurons exhibiting normal cell body diameters, even and continuous expression of YFP within all cell compartments, and more than two discernable primary dendrites with each more than two cell body-diameters long were scored as "healthy" (see Figure 3A) . 
